Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | SHBG | P04278 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 6/20 | 0.48 |
| ▸ | AR | P10275 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13965592 | 0.88 | LMNA (0.67) | LMNANR3C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL572198 | 0.88 | LMNA (0.67) | LMNANR3C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL853001 | 0.85 | LMNA (0.67) | LMNANR3C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9622429 | 0.85 | LMNA (0.67) | LMNANR3C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13941337 | 0.85 | LMNA (0.67) | LMNANR3C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9128581 | 0.85 | SHBG (0.65) | LMNANR3C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9128571 | 0.85 | SHBG (0.65) | LMNANR3C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15079258 | 0.84 | LMNA (0.49) | LMNANR3C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10444897 | 0.84 | LMNA (0.49) | LMNANR3C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10444770 | 0.84 | LMNA (0.49) | LMNANR3C1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0680970-B1 | Medrogestone | AMERICAN HOME PROD (US) | 2000-11-29 | — | — | EP | claimed |
| US-5519153-A | Medrogestone production | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-21 | — | — | US | claimed |
| EP-0680970-A2 | Medrogestrone | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-11-08 | — | — | EP | claimed |
| US-5428151-A | Medrogestrone production | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-06-27 | — | — | US | claimed |
| US-20210115084-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF NOMEGESTROL-ACETATE | RICHTER GEDEON NYRT. (HU) | 2021-04-22 | — | — | US | disclosed |
| EP-3555113-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF NOMEGESTROL-ACETATE | Richter Gedeon Nyrt. (HU) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109508-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF NOMEGESTROL-ACETATE | RICHTER GEDEON NYRT. (HU) | 2018-06-21 | — | — | WO | disclosed |
| EP-1841778-B1 | METHOD FOR PREPARING MEDROGESTONE | ABBOTT PRODUCTS GMBH (DE) | 2012-03-14 | — | — | EP | disclosed |
| EP-1841778-B1 | METHOD FOR PREPARING MEDROGESTONE | ABBOTT PRODUCTS GMBH (DE) | 2012-03-14 | — | — | EP | disclosed |
| EP-1841778-A1 | METHOD FOR PREPARING MEDROGESTONE | Solvay Pharmaceuticals GmbH (DE) | 2007-10-10 | — | — | EP | disclosed |
| EP-1841778-A1 | METHOD FOR PREPARING MEDROGESTONE | Solvay Pharmaceuticals GmbH (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20060178520-A1 | Process for preparing medrogestone | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-08-10 | — | — | US | disclosed |
| EP-0955049-A2 | 6 Beta-Hydroxy - 6 alpha, 17 alpha - dimethylpregn - 4 ene - 3,20 - dione, as an inhibitor of smooth muscle proliferation | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5523427-A | Medrogestone production | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-04 | — | — | US | disclosed |
| US-5519153-A | Medrogestone production | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-21 | — | — | US | disclosed |
| EP-0680970-A2 | Medrogestrone | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0680970-A2 | Medrogestrone | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-11-08 | — | — | EP | disclosed |
| US-5428151-A | Medrogestrone production | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-06-27 | — | — | US | disclosed |
| US-5428151-A | Medrogestrone production | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-06-27 | — | — | US | disclosed |
| US-4322349-A | Process for preparing 6-methylene steroids | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115084-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF NOMEGESTROL-ACETATE | CYP19A1, HSD17B11, CYP17A1 | LMNA 2746/4885NR3C1 460/4885MEN1 140/4885 |
| US-20060178520-A1 | Process for preparing medrogestone | CYP17A1, CYP19A1, HSD17B11 | LMNA 3659/4885NR3C1 53/4885MEN1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.